Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
about
Targeted therapy for advanced renal cell carcinomaA comprehensive overview of targeted therapy in metastatic renal cell carcinomamTOR inhibitors in advanced renal cell carcinomaState of the science: an update on renal cell carcinomaContemporary Treatment of Metastatic Renal Cell CarcinomaSaudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinomaBeyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinomaThe immunological effect of hyaluronan in tumor angiogenesisSequence of treatment in locally advanced and metastatic renal cell carcinomaImmune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With ImmunotherapyContemporary approaches for imaging skeletal metastasisMultidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvementThe impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic reviewProfile of tivozanib and its potential for the treatment of advanced renal cell carcinomaRole of immunotherapy for renal cell cancer in 2011Differentiating mTOR inhibitors in renal cell carcinomaAnti-angiogenesis and metastasis: a tumour and stromal cell alliancePD-1 as an emerging therapeutic target in renal cell carcinoma: current evidenceTargeted therapies and the treatment of non-clear cell renal cell carcinomaAxitinib in Metastatic Renal Cell CarcinomaTargeted therapy in advanced bladder cancer: what have we learned?Combination therapy for renal cell cancer: what are possible options?Individualising treatment choices in a crowded treatment algorithmEvaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinomaHypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell CarcinomaSunitinib in the treatment of metastatic renal cell carcinomaMedical treatment of renal cancer: new horizonsSafety and tolerability of pazopanib in the treatment of renal cell carcinomaFirst-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumorsImmunotherapy for metastatic renal cell carcinoma.Renal cell carcinoma.Prolonged survival after sequential multimodal treatment in metastatic renal cell carcinoma: two case reports and a review of the literature.Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.Antibody Therapies in Cancer.A phase I study of sunitinib plus bevacizumab in advanced solid tumors.Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.The role of anti-VEGF agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials.Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).
P2860
Q24242946-587E9EA4-DC18-4BDF-8CF1-9CA24F806EDEQ24606852-6936080B-E677-48E5-80E0-C76BEC016813Q24612127-8F75E0E1-4F6E-4780-979E-73C55A8BC8FFQ24630685-3BF90BB3-5382-4F3E-8815-FDABE8A1E719Q26740594-4B17951D-BA14-47B9-B554-6C4D9081A615Q26747767-DEE7E38D-8C83-42C5-99C7-B9A856B41411Q26766240-33D6A034-8033-4BF0-AFD8-F2015809AF6CQ26771483-B6FF44A9-2978-44F2-B1E0-58AE5C6A0C38Q26773653-09423832-C9BE-47D9-BE89-0F6A5610E11EQ26796309-C6ECC6CD-64B9-437B-8167-EDD30A9A225FQ26798170-31F21E84-752F-407C-8CD8-4A9F317FC37DQ26801279-0AD49A9D-B93E-4A7B-8DF8-D9D47BF5734BQ26824086-5FED032C-E2AE-453E-8A1B-EE5F7320906DQ26827319-69A72ADA-6F37-410B-8C3C-36947971503DQ26853453-E463D156-5431-4E1C-A78B-4ACC89043925Q26860172-7F9C1A25-FA62-4792-8ADA-A507E93FF266Q26862741-9A63D7B7-6B87-4D2C-906C-822AE59CAC27Q26865789-8ED48E87-5A8F-4500-A2DC-7DDC166E645AQ26995391-D38F884B-7131-4CA0-9078-A68BF7423129Q26998017-1B801E66-84F9-44D9-B33B-3D5EA13C63F7Q27009469-F1ED8D2C-55AD-4A06-9F85-E8F89837756BQ27011663-C90F2EB1-C2CF-4BCD-AB04-0F897461EE9BQ27023669-EB73F1DF-15EE-4DF7-9909-68D581C7F059Q27028048-D7D936C7-F9DE-48D0-B2FB-7DCBF2D15654Q28066747-F15A40DC-6450-4315-9810-95D9C49EBC91Q28072057-9F5B5807-C499-4392-8FE2-0A27A50AEDF5Q28073174-9B6AC9EA-F230-4313-9265-11E5ACDEE9B2Q28272429-93985A9A-6133-4010-BBA6-F34C9CB4EAC0Q28537681-B712FAD0-E8D8-4E7C-BC23-0DE74C1A97D7Q30234458-45AC2121-9124-4D00-BB80-E0F238FA0D38Q30235364-DFE3086E-C45A-47FA-91B1-FE6507411123Q30565687-2DFE97CE-8248-4710-B6A1-B4F0181CA2C8Q31060162-59111D09-2E82-4575-B475-6B3A2A913DD9Q31104000-BA11FBE4-BF27-40CB-A3DE-A36E915FB2D5Q33386345-69853DF4-71AB-4F5C-AE36-25552B4D7B4FQ33387073-91B00663-2D38-4EE6-8507-AB0F1C748C11Q33399152-AD21E8F4-3184-4CD0-A69B-889D8B43C722Q33403399-FBD30A0C-F090-4B47-9A38-4420811595DFQ33415118-AF4FC307-7E45-4644-88C9-63905E0F7070Q33417698-9132645D-EC3D-49EB-8D36-AB48BF09B719
P2860
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bevacizumab plus interferon al ...... al cell carcinoma: CALGB 90206
@en
Bevacizumab plus interferon al ...... l cell carcinoma: CALGB 90206.
@nl
type
label
Bevacizumab plus interferon al ...... al cell carcinoma: CALGB 90206
@en
Bevacizumab plus interferon al ...... l cell carcinoma: CALGB 90206.
@nl
prefLabel
Bevacizumab plus interferon al ...... al cell carcinoma: CALGB 90206
@en
Bevacizumab plus interferon al ...... l cell carcinoma: CALGB 90206.
@nl
P2093
P2860
P356
P1476
Bevacizumab plus interferon al ...... al cell carcinoma: CALGB 90206
@en
P2093
Brian I Rini
Daniel A Vaena
Eric J Small
James N Atkins
Janice Dutcher
Joel Picus
Jonathan E Rosenberg
Laura Archer
Piotr Czaykowski
San-San Ou
P2860
P304
P356
10.1200/JCO.2008.16.9847
P407
P577
2008-10-20T00:00:00Z